BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gualtierotti R, Ingegnoli F, Meroni PL. Pre-conceptional exposure to rituximab: comment on the article by Ojeda-Uribe et al. Clin Rheumatol 2013;32:727-8. [PMID: 23636791 DOI: 10.1007/s10067-013-2241-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
Number Citing Articles
1 Schioppo T, Ingegnoli F. Current perspective on rituximab in rheumatic diseases. Drug Des Devel Ther 2017;11:2891-904. [PMID: 29042750 DOI: 10.2147/DDDT.S139248] [Cited by in Crossref: 46] [Cited by in F6Publishing: 17] [Article Influence: 11.5] [Reference Citation Analysis]
2 Tavakolpour S, Alesaeidi S, Darvishi M, GhasemiAdl M, Darabi-Monadi S, Akhlaghdoust M, Elikaei Behjati S, Jafarieh A. A comprehensive review of rituximab therapy in rheumatoid arthritis patients. Clin Rheumatol 2019;38:2977-94. [PMID: 31367943 DOI: 10.1007/s10067-019-04699-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 10.5] [Reference Citation Analysis]
3 Gerosa M, Meroni PL, Cimaz R. Safety considerations when prescribing immunosuppression medication to pregnant women. Expert Opinion on Drug Safety 2014;13:1591-9. [DOI: 10.1517/14740338.2014.951326] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]